Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

109.19 -1.34 (-1.21%)

Official Closing Price Updated: 7:00 PM EST, Jan 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

99 100 Next >

Rosen Law Firm Urges Merck & Co., Inc. (NYSE: MRK) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

February 13, 2025

From The Rosen Law Firm, P.A.

Via Business Wire

Robert F. Kennedy, Vaccine Skeptic, Confirmed As Trump's Secretary Of Health: Health Care Stocks To Watch ↗

February 13, 2025

The U.S. Senate voted on Thursday to confirm President Donald Trump's nomination of Robert F. Kennedy Jr. to lead the Department of Health and Human Services.

Via Benzinga

Topics Government

3 Blue-Chip Dividend Stocks Trading at Multiyear Lows ↗

February 13, 2025

Via The Motley Fool

Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever. ↗

February 13, 2025

Via The Motley Fool

Rosen Law Firm Encourages Merck & Co. Inc. Investors to Inquire About Securities Class Action Investigation – MRK

February 12, 2025

From The Rosen Law Firm, P.A.

Via Business Wire

Recent Filing Shows That Rep. Josh Gottheimer Sold Over $54K Worth of Merck & Co Stock ↗

February 11, 2025

Via Benzinga

Market Whales and Their Recent Bets on MRK Options ↗

February 06, 2025

Via Benzinga

Neuphoria Stock Jumps On Triggering $15M Milestone Payment From Merck For Alzheimer's Study: Retail Interest Explodes ↗

February 12, 2025

This payment represents the second milestone in the collaboration between Neuphoria and Merck, with Neuphoria potentially eligible for up to $450 million in additional milestone payments.

Via Stocktwits

Gilead Sciences Beats Q4 EPS Forecast ↗

February 11, 2025

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

Via The Motley Fool

Merck Stock Heads For 5th Day Of Losses As TD Cowen Downgrades On Gardasil Woes, But Retail Holds Strong ↗

February 10, 2025

The HPV vaccine had been a key growth driver in China until last year when economic headwinds disrupted demand.

Via Stocktwits

Merck: 4 No-Brainer Reasons to Buy This Dip

February 10, 2025

Merck & Co. stock was pummeled by 10% after its earnings release on soft forecasts, but the overreaction by the market may present a buying opportunity.

Via MarketBeat

Better High-Yield Dividend Stock: Pfizer vs. Merck ↗

February 10, 2025

Via The Motley Fool

Top 3 Health Care Stocks You'll Regret Missing This Month ↗

February 06, 2025

Via Benzinga

Why Merck Stock Is Plummeting Today ↗

February 04, 2025

Via The Motley Fool

Merck Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

February 06, 2025

From Merck & Co., Inc.

Via Business Wire

Analysts Defend Merck Amid Investor Concerns Over Weak Guidance ↗

February 05, 2025

Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a lower-than-expected 2025 outlook.

Via Benzinga

Uncover the latest developments among S&P500 stocks in today's session. ↗

February 04, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top S&P500 gainers and losers in today's session.

Via Chartmill

Merck (MRK) Q4 2024 Earnings Call Transcript ↗

February 04, 2025

MRK earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

Looking for the most active stocks in the S&P500 index on Tuesday? ↗

February 04, 2025

Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Tuesday and discover the stocks that are dominating the trading activity and setting the pace for...

Via Chartmill

Merck Retail Traders See Buying Opportunity As Stock Dives Toward Worst Day in 17 Years On Weak Guidance ↗

February 04, 2025

Gardasil, its HPV vaccine, posted a 17% decline in sales to $1.55 billion, primarily due to lower demand in China.

Via Stocktwits

Curious about which S&P500 stocks are generating unusual volume on Tuesday? Find out below. ↗

February 04, 2025

Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Tuesday. Stay informed about the market activity below.

Via Chartmill

Discover which S&P500 stocks are making waves on Tuesday. ↗

February 04, 2025

Get insights into the S&P500 index performance on Tuesday. Explore the top gainers and losers within the S&P500 index in today's session.

Via Chartmill

US Stocks Rise Despite China's Trade Fears, Palantir Defies Gravity, Gold Rallies Further: What's Driving Markets Tuesday? ↗

February 04, 2025

U.S. stocks advanced midday Tuesday, demonstrating resilience despite escalating geopolitical tensions and trade uncertainties between the world’s two largest economies.

Via Benzinga

Why Merck (MRK) Stock Is Falling Today

February 04, 2025

Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed fourth-quarter earnings. Its full-year revenue and EPS guidance missed by a...

Via StockStory

Gapping S&P500 stocks in Tuesday's session ↗

February 04, 2025

Curious about the market action on Tuesday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.

Via Chartmill

Get insights into the top movers in the S&P500 index of Tuesday's pre-market session. ↗

February 04, 2025

The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.

Via Chartmill

Merck Tops Q4 Earnings And Revenue Estimates ↗

February 04, 2025

Merck came out with quarterly earnings of $1.72 per share.

Via Talk Markets

Topics Stocks / Equities

Merck's Gardasil Vaccine Slowdown In China Bites Again, Stock Falls On Weak 2025 Outlook ↗

February 04, 2025

Merck posted Q4 sales of $15.62 billion, driven by Keytruda's 19% growth. FY25 guidance lags estimates, citing Gardasil shipment pause in China and forex impact.

Via Benzinga

PayPal, Estée Lauder, UBS And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

February 04, 2025

Via Benzinga

Merck’s (NYSE:MRK) Q4 Sales Top Estimates But Stock Drops

February 04, 2025

Global pharmaceutical company Merck (NYSE:MRK) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 6.8% year on year to $15.62 billion. On the other hand, the company’s...

Via StockStory

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.